Dogecoin Funding Rates Turn Negative As Short Sellers Eye Further Losses
Dogecoin (CRYPTO: DOGE) is beginning to see a surge in short bets as the broader meme sector experiences a downturn, raising concerns about the stability of meme co
Smart Money Is Betting Big In HOOD Options
Investors with a lot of money to spend have taken a bullish stance on Robinhood Markets (NASDAQ:HOOD). And…
Joby Aviation Opens Slightly Lower After FAA Gives Nod To Air-Taxi Software
Joby Aviation intends to utilize ElevateOS for its air taxi operations and make it available to select partners who purchase their aircraft.
Market Whales and Their Recent Bets on FSLR Options
Whales with a lot of money to spend have taken a noticeably bearish stance on First Solar. Looking…
Spotlight on CrowdStrike Holdings: Analyzing the Surge in Options Activity
Deep-pocketed investors have adopted a bearish approach towards CrowdStrike Holdings (NASDAQ:CRWD), and it’s something market players shouldn’t ignore.…
Recreation Products Maker Winnebago Struggles In Q3 With Lower Earnings, But New Product Launches Offer Hope: Details
Winnebago Industries shares drop post-Q3 earnings miss with lower revenues and decreased gross profit margins amid challenging market conditions.
Cava Group’s Options Frenzy: What You Need to Know
Investors with a lot of money to spend have taken a bearish stance on Cava Group (NYSE:CAVA). And…
ARM Holdings Options Trading: A Deep Dive into Market Sentiment
High-rolling investors have positioned themselves bearish on ARM Holdings (NASDAQ:ARM), and it’s important for retail traders to take…
Unpacking the Latest Options Trading Trends in Broadcom
Deep-pocketed investors have adopted a bearish approach towards Broadcom (NASDAQ:AVGO), and it’s something market players shouldn’t ignore. Our…
What’s Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients using TPST-1120 combined with atezolizumab and bevacizumab.